> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Will Review Lucentis Biosimilar BLA
- URL: https://www.fdaweb.com/fda-will-review-lucentis-biosimilar-bla/
- Published: 2020-11-18T12:00:00.000Z
- Updated: 2026-09-14T16:36:49.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5148121

FDA has accepted for review a BLA submitted by Samsung Bioepis and Biogen for their SB11, a proposed biosimilar referencing Genentech’s Lucentis (ranibizumab). Lucentis is an anti-VEGF (vascular endothelial growth factor) therapy for retinal vascular disorders.

Samsung Bioepsis said in 11/2019 that it had entered into a commercialization agreement with Biogen for two ophthalmology biosimilar candidates, ranibizumab and aflibercept in the U.S. and several other countries.